In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Repetitive Transcranial Magnetic Stimulation for the Treatment of Fibromyagia: An Open-Label Trial

    Final Number:
    4059

    Authors:
    Nilson Nogueira Mendes Neto MS; Jessika Thais da Silva Maia; Marcelo Rodrigues Zacarkim MD; Waleska Jessiane do N. Freitas RN; Juliéli Naiane Teixeira MS; Levi H. MD Jales Jr.

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2017 Annual Meeting - Late Breaking Science

    Introduction: Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive neuromodulation technique that has been used to treat patients with fibromyalgia (FM). Data regarding to its efficacy is lacking.

    Methods: Open-label uncontrolled clinical trial where 17 subjects diagnosed with FM were enrolled. The recruitment period was from January 2015 to May 2017 and all subjects should have received rTMS in the left prefrontal cortex. The sessions were performed in a series of 3 to 5 consecutive days with maximum break of 2 days between the series. A minimum of 10 sessions was required. Parameters used: frequency (10Hz), cycles of 10 stimuli with pause of 20 seconds between them. 20 minutes was the length of each session. Motor threshold was adjusted according to the acceptance of patients. Variables such as side effects, pain, depressive symptoms, insomnia, fatigue, quality of life and side effects were assessed after each session.

    Results: Among the 17 patients, 88.2% were women. Mean sample age of 55.7 years (ranging from 31-81 years) .41.2% reported significant improvement of pain after 3rd rTMS session. Improvement of depressive symptoms was observed after 3rd sessions in 50% of patients. Improvement of insomnia and fatigue was reported after 3rd sessions in 52.9% in 35.3% of patients, respectively. Increased quality of life was seen in 47.1% of patients after the 3rd session. Three patients report mild and transient symptoms such as tinnitus and headache.

    Conclusions: In our experience, rTMS had a significant influence on the reduction of diffuse pain in patients with FM. In addition, it showed to be a good option for rapid relief of since most patients reported relief of symptoms after the third session. rTMS was well tolerated with minimal adverse effects. Additional studies are needed to determine optimal protocols for the use of rTMS in the treatment of FM.

    Patient Care: Due to lack of data about the use of rTMS (efficacy and safety) for the treatment of FM, this study may contribute to elucidate these questions that are not still well known.

    Learning Objectives: To evaluate the efficacy and safety of rTMS as a treatment for FM in a center for diagnosis and treatment of pain.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy